Baumgart DC. Extended colonic release low-molecular weight heparin (LMWH) not ready for use in ulcerative colitis. Evid Based Med. 2011;16:71–2.PubMed

Tytgat GN, Van Nueten L, Van De Velde I, Joslyn A, Hanauer SB. Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies. Aliment Pharmacol Ther. 2002;16:87–99.PubMed

Skandalis N, Rotenberg A, Meuwissen S, deGroot GH, Ouwendijk RJT, Tan TG. Ridogrel for the treatment of mild to moderate ulcerative colitis. Gastroenterology. 1996;110:A1016.

Auwerda JJ, Zijlstra FJ, Tak CJ, van den Ingh HF, Wilson JH, Ouwendijk RJ. Ridogrel enemas in distal ulcerative colitis. Eur J Gastroenterol Hepatol. 2001;13:397–400.PubMed

Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, Droge W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut. 1998;42:485–92.PubMedCentralPubMed

Guijarro LG, Mate J, Gisbert JP, et al. N-acetyl-l-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. World J Gastroenterol. 2008;14:2851–7.PubMedCentralPubMed

Celinski K, Dworzanski T, Korolczuk A, et al. Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats. J Physiol Pharmacol. 2011;62:347–56.PubMed

Celinski K, Madro A, Prozorow-Krol B, et al. Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR- g)-specific agonist, as a modulator in experimental acute pancreatitis. Med Sci Monit. 2009;15:21–9.

Celinski K, Dworzanski T, Prozorow-Krol B, Korolczuk A. The role of PPAR-g receptors in gastrointestinal inflammation diseases. Gastroenterol Pol. 2009;16:51–6.

Andersen V, Christensen J, Ernst A, et al. Polymorphisms in NF-kB, PXR, LXR, PPARg and risk of inflammatory bowel disease. World J Gastroenterol. 2011;17:197–206.PubMedCentralPubMed

Hontecillas R, Horne WT, Climent M, et al. Immunoregulatory mechanisms of macrophage PPAR-g in mice with experimental inflammatory bowel disease. Mucosal Immunol. 2011;4:304–13.PubMedCentralPubMed

Saraf N, Sharma PK, Mondal SC, Garg VK, Singh AK. Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. J Pharm Pharmacol. 2012;64:161–71.PubMed

Xiang GQ, Tang SS, Jiang LY, et al. PPARg agonist pioglitazone improves scopolamine-induced memory impairment in mice. J Pharm Pharmacol. 2012;64:589–96.PubMed

Ma JJ, Zhang T, Fang N, Zou Y, Gong QH, Yu LM, Chen DX. Establishment of a cell-based drug screening model for identifying agonists of human peroxisome proliferator activated receptor gamma (PPARg). J Pharm Pharmacol. 2012;64:719–26.PubMed

Rossi A, Kapahi P, Natoli G, et al. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature. 2000;403:103–8.PubMed

Saubermann LJ, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis. 2002;8:330–9.PubMed

Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol. 2001;96:3323–8.PubMed

Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008;134:688–95.PubMedCentralPubMed

Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL. Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes. 2010;3:538–45.PubMed

Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004;19:739–47.PubMed

Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid induced colitis in mice. Gastroenterology. 2002;123:1912–22.PubMed

Deguchi Y, Andoh A, Inatomi O, Yagi Y, Bamba S, Araki Y, et al. Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. Dig Dis Sci. 2007;52:2993–8.PubMed

Arafa HM, Hemeida RA, El-Bahrawy AI, Hamada FM. Prophylactic role of curcumin in dextran sulfate sodium(DSS)-induced ulcerative colitis murine model. Food Chem Toxicol. 2009;47:1311–7.PubMed

Venkataranganna MV, Rafiq M, Gopumadhavan S, Peer G, Babu UV, Mitra SK. NCB-02 (standardized Curcumin preparation) protects dinitrochlorobenzene-induced colitis through down-regulation of NFkappa-B and iNOS. World J Gastroenterol. 2007;13:1103–7.PubMedCentralPubMed

Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502–6.PubMed

University of Maryland Medical center. http://​www.​umm.​edu/​altmed/​articles/​turmeric-000277.​htm (2012). Accessed 14 October 2014.

Lahiff C, Moss AC. Curcumin for clinical and endoscopic remission in ulcerative colitis. Inflamm Bowel Dis. 2011;17(7):E66.PubMed

Anthoni C, Laukoetter MG, Rijcken E, et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1131–7.PubMed

Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2:37–43.PubMed

Holtmeier W, Zeuzem S, Preiss J, et al. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn’s disease: good safety profile but lack of efficacy. Inflamm Bowel Dis. 2011;17:573–82.PubMed

Hilsden RJ, Verhoef MJ, Rasmussen H, Porcino A, DeBruyn JC. Use of complementary and alternative medicine by patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:655–62.PubMed

Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR, Ware JH. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci. 2008;53:175–80.PubMed